CA2540214A1 - 2,4-dioxo-3-quinazolinylaryl sulfonylureas - Google Patents
2,4-dioxo-3-quinazolinylaryl sulfonylureas Download PDFInfo
- Publication number
- CA2540214A1 CA2540214A1 CA002540214A CA2540214A CA2540214A1 CA 2540214 A1 CA2540214 A1 CA 2540214A1 CA 002540214 A CA002540214 A CA 002540214A CA 2540214 A CA2540214 A CA 2540214A CA 2540214 A1 CA2540214 A1 CA 2540214A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- alkoxy
- cycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940100389 Sulfonylurea Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 50
- 229910052736 halogen Inorganic materials 0.000 claims abstract 43
- 150000002367 halogens Chemical class 0.000 claims abstract 43
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 30
- 125000000217 alkyl group Chemical group 0.000 claims abstract 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 23
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract 17
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract 10
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000005647 linker group Chemical group 0.000 claims abstract 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000003118 aryl group Chemical group 0.000 claims abstract 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 6
- 208000007536 Thrombosis Diseases 0.000 claims abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 58
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 40
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 26
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 23
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 23
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 17
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 17
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 14
- -1 cyano, hydroxy Chemical group 0.000 claims 14
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 9
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 8
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 4
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 4
- 229930192474 thiophene Natural products 0.000 claims 4
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000000702 anti-platelet effect Effects 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 206010050496 Reversible ischaemic neurological deficit Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 206010043647 Thrombotic Stroke Diseases 0.000 claims 1
- 102000003938 Thromboxane Receptors Human genes 0.000 claims 1
- 108090000300 Thromboxane Receptors Proteins 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 229940072645 coumadin Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 229940118179 lovenox Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50856403P | 2003-10-03 | 2003-10-03 | |
| US60/508,564 | 2003-10-03 | ||
| PCT/US2004/032921 WO2005032488A2 (en) | 2003-10-03 | 2004-09-29 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2540214A1 true CA2540214A1 (en) | 2005-04-14 |
Family
ID=34421757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002540214A Abandoned CA2540214A1 (en) | 2003-10-03 | 2004-09-29 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7109332B2 (enExample) |
| EP (1) | EP1668002B1 (enExample) |
| JP (1) | JP2007507551A (enExample) |
| KR (1) | KR20060113700A (enExample) |
| CN (1) | CN1863798B (enExample) |
| AT (1) | ATE448222T1 (enExample) |
| AU (1) | AU2004278030C1 (enExample) |
| CA (1) | CA2540214A1 (enExample) |
| DE (1) | DE602004024093D1 (enExample) |
| ES (1) | ES2334795T3 (enExample) |
| IL (1) | IL174446A (enExample) |
| MX (1) | MXPA06003618A (enExample) |
| PL (1) | PL1668002T3 (enExample) |
| PT (1) | PT1668002E (enExample) |
| WO (1) | WO2005032488A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2390520C2 (ru) * | 2003-12-22 | 2010-05-27 | Адзиномото Ко., Инк. | Новые производные фенилаланина |
| WO2006039212A2 (en) * | 2004-09-29 | 2006-04-13 | Portola Pharmaceuticals, Inc. | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
| AU2006311795B2 (en) * | 2005-11-03 | 2013-01-17 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| US7834023B2 (en) * | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
| CA2682207A1 (en) | 2007-04-05 | 2008-10-16 | Cv Therapeutics, Inc. | Quinazolinone derivatives as aldh-2 inhibitors |
| WO2008133155A1 (ja) | 2007-04-19 | 2008-11-06 | Astellas Pharma Inc. | 二環式ヘテロ環化合物 |
| KR20100020455A (ko) * | 2007-05-02 | 2010-02-22 | 포톨라 파마슈티컬스, 인코포레이티드 | 상이한 결정질 형태의 [4-(6-플루오로-7-메틸아미노-2,4-디옥소-1,4-디히드로-2ｈ-퀴나졸린-3-일)-페닐]-5-클로로-티오펜-2-일-술포닐우레아염, 및 이의 제약 조성물 |
| CN101654441B (zh) * | 2008-08-19 | 2012-10-03 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
| AU2010204555B2 (en) | 2009-01-19 | 2013-03-07 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN102282129A (zh) | 2009-01-19 | 2011-12-14 | 雅培制药有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| KR20140091022A (ko) | 2011-10-31 | 2014-07-18 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| PE20150400A1 (es) | 2012-05-22 | 2015-03-27 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor |
| WO2014008458A2 (en) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| MX2015011436A (es) | 2013-03-14 | 2016-06-06 | Genentech Inc | Triazolopiridinas sustituidas y metodos para usarlas. |
| MX2015010775A (es) | 2013-03-15 | 2016-04-25 | Genentech Inc | Benzoxazoles sustituidos y metodos para usarlos. |
| CN105793238B (zh) | 2013-11-27 | 2019-12-24 | 基因泰克公司 | 经取代的苯甲酰胺及其使用方法 |
| EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CN113582889B (zh) | 2015-02-16 | 2024-09-20 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| US10179767B2 (en) | 2015-05-22 | 2019-01-15 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| KR20190078587A (ko) | 2016-10-17 | 2019-07-04 | 제넨테크, 인크. | 치료 화합물 및 그의 사용 방법 |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| WO2019008025A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| WO2019034692A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| BR112020003014A2 (pt) | 2017-08-15 | 2020-07-28 | Inflazome Limited | sulfonilureias e sulfoniltioureias como inibidores de vnlrp3 |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| CA3078195A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11028075B2 (en) | 2018-02-26 | 2021-06-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CN113164481B (zh) | 2018-12-06 | 2024-08-30 | 第一三共株式会社 | 环烷-1,3-二胺衍生物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| EP1047699A1 (en) | 1998-01-15 | 2000-11-02 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| ES2252193T3 (es) * | 2000-02-04 | 2006-05-16 | Portola Pharmaceuticals, Inc. | Inhibidores de receptores de adp de plaquetas. |
-
2004
- 2004-09-29 JP JP2006534290A patent/JP2007507551A/ja active Pending
- 2004-09-29 EP EP04789522A patent/EP1668002B1/en not_active Expired - Lifetime
- 2004-09-29 ES ES04789522T patent/ES2334795T3/es not_active Expired - Lifetime
- 2004-09-29 WO PCT/US2004/032921 patent/WO2005032488A2/en not_active Ceased
- 2004-09-29 CA CA002540214A patent/CA2540214A1/en not_active Abandoned
- 2004-09-29 AU AU2004278030A patent/AU2004278030C1/en not_active Ceased
- 2004-09-29 US US10/956,004 patent/US7109332B2/en not_active Expired - Fee Related
- 2004-09-29 AT AT04789522T patent/ATE448222T1/de active
- 2004-09-29 KR KR1020067008644A patent/KR20060113700A/ko not_active Ceased
- 2004-09-29 PT PT04789522T patent/PT1668002E/pt unknown
- 2004-09-29 PL PL04789522T patent/PL1668002T3/pl unknown
- 2004-09-29 DE DE602004024093T patent/DE602004024093D1/de not_active Expired - Lifetime
- 2004-09-29 CN CN2004800287913A patent/CN1863798B/zh not_active Expired - Fee Related
- 2004-09-29 MX MXPA06003618A patent/MXPA06003618A/es active IP Right Grant
-
2006
- 2006-03-21 IL IL174446A patent/IL174446A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1863798A (zh) | 2006-11-15 |
| PT1668002E (pt) | 2009-11-25 |
| WO2005032488A3 (en) | 2005-05-12 |
| HK1093973A1 (en) | 2007-03-16 |
| JP2007507551A (ja) | 2007-03-29 |
| WO2005032488A2 (en) | 2005-04-14 |
| EP1668002A4 (en) | 2006-12-20 |
| US20050107357A1 (en) | 2005-05-19 |
| MXPA06003618A (es) | 2006-08-11 |
| EP1668002B1 (en) | 2009-11-11 |
| PL1668002T3 (pl) | 2010-02-26 |
| AU2004278030B2 (en) | 2010-07-01 |
| DE602004024093D1 (de) | 2009-12-24 |
| US7109332B2 (en) | 2006-09-19 |
| AU2004278030C1 (en) | 2010-12-02 |
| KR20060113700A (ko) | 2006-11-02 |
| EP1668002A2 (en) | 2006-06-14 |
| CN1863798B (zh) | 2011-08-31 |
| IL174446A (en) | 2012-02-29 |
| IL174446A0 (en) | 2006-08-01 |
| AU2004278030A1 (en) | 2005-04-14 |
| ATE448222T1 (de) | 2009-11-15 |
| ES2334795T3 (es) | 2010-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2540214A1 (en) | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | |
| JP2007507551A5 (enExample) | ||
| DE69408750T2 (de) | 4-Aminopyrimidin Derivate | |
| JP2007507519A5 (enExample) | ||
| AU751139B2 (en) | Amide derivative | |
| JP2008517983A5 (enExample) | ||
| BR112020000553A2 (pt) | carboxamidas como moduladores de canal de sódio | |
| MX2007003836A (es) | 2h-1,3-benzoxazin-4(3h)-onas sustituidas. | |
| NO941101L (no) | Quinazolin-derivater | |
| JPH07507072A (ja) | 糖尿病の合併症を制御する置換ピリミジン類 | |
| MX2009010790A (es) | Derivados de heteroarilo biciclico fusionados. | |
| KR920021541A (ko) | 벤조푸란 유도체 | |
| RU2005112752A (ru) | Производные пиридина в качестве модуляторов рецептора сb2 | |
| KR920006322A (ko) | 벤젠, 피리딘 및 피리미딘 유도체 | |
| NO20060206L (no) | Nye azetidinforbindelser | |
| RU2004130487A (ru) | Производные азетидина в качестве антагонистов ccr-3 рецептора | |
| RU2008118201A (ru) | Антагонист рецептора s1p3 | |
| US5612365A (en) | Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease | |
| CA2626402A1 (en) | Potassium channel inhibitors | |
| CA2388470A1 (en) | Use of carbonylamino derivatives against cns disorders | |
| KR100345187B1 (ko) | 트롬복산a2-개재된질환의예방및치료제 | |
| RU2002110106A (ru) | Новые производные пиримидин-2, 4,6-трионов, способ их получения и фармацевтические средства, содержащие эти соединения | |
| KR960704853A (ko) | 피리다지논 유도체 또는 그의 염, 그의 제조 방법 및 그를 함유하는 항쇼크제 (Pyridazinone Derivatives or their Salts, Processes for their Production, and Anti-Shock Agents Containing Them) | |
| CA2290557C (en) | Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-.beta.1 | |
| TR200301890T2 (tr) | HIV-İnhibe edici N-Aminoimidazol türevleri. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130502 |